To wait for resistance to drugs to develop in patients and then identify why it happened, will lead to a deadly lag in the design of salvage therapies or indeed preventative treatment approaches.
In our latest manuscript we describe a systematic analysis of negative selection pressures acting on neoantigen forming mutations. Contrary to what is generally believed we did not find any clear evidence of this immunogenic form of selection and the resulting neoantigen depletion.
In the November issue of Nature Medicine we describe the development of a first-in-class inhibitor of CLCF1 signaling and its effectiveness in several precllinical models of lung adenocarcinoma
The review introduces the idea of the PGC-1/ERR transcriptional network such as a novel category of metabolic target that could be useful for exploitation in future research in precision oncology. It addresses the concept of therapeutically explore biological capabilities acquired during the development of cancer to improve patient care against therapeutic resistance. What is the potential therapeutic target for cancer metabolism? If it exists, we do believe that targeting the PGC-1/ERR network as a mitochondrial vulnerability of metabolic-addictive cancers is a great opportunity to improve patient care. How to study it? The authors think that studying the PGC-1/ERR protein complex in its native state could shed new light on the mechanism of cancer resistance. As a potential tool, single-particle cryo-electron microscopy (cryo-EM) is urgently needed to develop a high-resolution biological structure to fully elucidate the function and molecular biology of the PGC-1/ERR network. In parallel, it would provide the identification of novel binding partners in signal transduction cascades that might have clinical relevance to improve patient care against therapeutic resistance. Here, the author tells the real story behind the paper, explaining what did motivate the authors to write this review? What is the biggest challenge to consider in the field of cryo-electron microscopy? And what next for further exacerbate our hope to improve patient care.
The paper introduces AI and its applications in precision oncology. It discusses major advances and challenges beyond pattern recognition and classification tasks. It argues in favor of wider innovative uses of AI for bringing benefits to patients.
In this post, the author talks about the motivation behind the paper, important topics not covered in it and the excitement of doing research in this field.
In oncology research, the CRISPR technology provides a very powerful tool to support the investigation of the relationships between genes and phenotypes.
We and selected partners, use cookies or similar technologies as specified in the cookie policy and privacy policy.
You can consent to the use of such technologies by closing this notice.
×
Cookie Control
Customise your preferences for any tracking technology
The following allows you to customize your consent preferences for any tracking technology used
to help us achieve the features and activities described below. To learn more about how these trackers help us
and how they work, refer to the cookie policy. You may review and change your preferences at any time.
These trackers are used for activities that are strictly necessary to operate or deliver the service you requested from us and, therefore, do not require you to consent.
These trackers help us to provide a personalized user experience by improving the quality of your preference management options, and by enabling the interaction with external networks and platforms.
Nature Portfolio Cancer Community is for all those interested in cancer research, including our journal readers and authors, educators, and those working in medicine, industry and healthcare